Genomics and Isolation Core

基因组学和分离核心

基本信息

批准号：
10219122
负责人：
Lorenzo Giacani
金额：
$ 42.38万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-01 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10219122
关键词：
Animals Antigenic Variation Biological Biological Specimen Banks Centers for Disease Control and Prevention (U.S.)Characteristics Chemistry Clinical Collection Complex DNA DNA sequencing Databases Development Epidemiology Equipment and supply inventories Exudate Genes Genetic Genome Genomics Geographic Locations Geography Goals Growth Immunization Infection Joints Knowledge Laboratories Libraries Location Maintenance Manuscripts Methods Modeling Modernization Molecular Molecular Medicine Nucleic Acid Amplification Tests Nucleic Acids Oligonucleotides Oryctolagus cuniculus Patients Peer Review Population Primary Lesion Process Publishing Quality Control Research Research Personnel Sampling Scientist Secondary Lesion Secure Sexually Transmitted Diseases Shotguns Site Specimen Swab Syphilis Testing Testis Time Treponema pallidum Universities Vaccine Design Variant Viral Virulence Washington Work comparative data submission deep sequencing design experience experimental study genetic variant genome sequencing laboratory facility next generation next generation sequencing pathogen repository response syphilis vaccine vaccine candidate vaccine development vaccine efficacy vaccine evaluation whole genome

项目摘要

ABSTRACT The goal of our STI CRC U19 is to use knowledge acquired over decades of research to develop an effective vaccine for syphilis. Two necessary components for the development of a syphilis vaccine are i) the identification of genetic variants for selected vaccine candidates in the circulating pathogen population to inform vaccine development, and ii) the isolation of modern syphilis strains, that best reflect the genetic background and virulence characteristics of circulating pathogens and that can be used for animal challenge following immunization experiments. These are the goals of the Genomics and Isolation Core. Over the three years of activity of this Core, we will use biological samples recently collected from syphilis- infected patients to extract and enrich for Treponema pallidum DNA, and perform next-generation whole genome sequencing of several hundred genomes of the syphilis agent. Such samples, collected from the geographically diverse locations, will provide a deeper understanding of the antigenic variability resulting from differences in the genes encoding our selected vaccine candidates. Additionally, we will isolate modern treponemal strains from biological samples (primary or secondary lesion exudates) collected from early syphilis patients to provide alternatives to historical syphilis isolates for animal challenge experiments. The work we will conduct in this Genomics and Isolation Core will be a critical component of this outstanding effort to develop a syphilis vaccine.

抽象的我们的STI CRC U19的目标是使用数十年来研究的知识来开发有效的梅毒疫苗。梅毒疫苗开发的两个必要组件是我）鉴定循环病原体中选定疫苗的遗传变异为疫苗开发提供信息，ii）现代梅毒菌株的隔离，最好反映遗传循环病原体的背景和毒力特征，可用于动物免疫实验后的挑战。这些是基因组学和孤立核心的目标。在该核心的三年活动中，我们将使用最近从梅毒中收集的生物样品感染的患者提取并富集treponema pallidum DNA，并进行下一代梅毒剂的几百个基因组的基因组测序。这样的样本，从地理上不同的位置将对导致的抗原变异性有更深入的了解从编码我们所选疫苗候选物的基因的差异中。此外，我们将隔离从生物样品（原发性或次要病变渗出液）中收集的现代蛋白酶菌株早期的梅毒患者为动物挑战实验提供了历史梅毒分离株的替代方法。我们将在此基因组学和隔离核心中进行的工作将是其中的关键组成部分开发梅毒疫苗的杰出努力。